Alnylam's Amvuttra Tests Faster HTA In England, Wins Praise in Germany For Full Assessment

 
• By Francesca Bruce

Alnylam has opted to submit its orphan drug Amvuttra for a full benefit assessment in Germany, rather than an abbreviated process that requires no comparative data. In England, the drug was recommended following a pilot for designing a new and faster approach to health technology appraisals.

Amyloidosis
English And German HTA Bodies Consider Alnylam's Amvuttra for hereditary transthyretin-related amyloidosis • Source: Shitterstock

More from Europe

More from Geography